EUVIMEDEUVIMED entdecken
Crossref

Bis(benzimidazol‐2‐yl)amine‐Based DPP‐4 Inhibitors Potentially Suitable for Combating Diabetes and Associated Nervous System Alterations

Katarina Tomović Pavlović, Budimir S Ilić, Luisa Leitzbach, Kameliya K Anichina, Denitsa Yancheva, Aleksandra Živković, Anelia Ts Mavrova, Holger Stark, Andrija Šmelcerović

Chemistry & Biodiversity · 2024

DOI: 10.1002/cbdv.202401227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Katarina Tomović Pavlović und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Medicine, University of Niš, Bulevar Dr Zorana Đinđića 81, 18000, Niš, Serbia. Hauptthemen laut MEDLINE: Benzimidazoles, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Ministry of Science, Technological Development and Innovation, European Union - NextGenerationEU, National Recovery and Resilience Plan of the Republic of Bulgaria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bis(benzimidazol‐2‐yl)amine scaffold is not present in dipeptidyl peptidase‐4 (DPP‐4) inhibitors published so far. Herein, the inhibitory potential of bis(benzimidazol‐2‐yl)amine derivatives against DPP‐4 was evaluated. In non‐competitive inhibition mode, three representatives 5 , 6 , and 7 inhibited DPP‐4 in vitro with IC 50 values below 50 μM. The assessed binding pocket of DPP‐4 for these benzimidazoles includes the S2 extensive subsite's residues Phe357 and Arg358. None of the lead compounds showed cytotoxicity to human neuroblastoma SH‐SY5Y cells at concentrations lower than 10 μM. None showed significant binding affinity at dopamine D 2 , D 3, and histamine H 1 , H 3 receptors, at concentrations lower than 10 μM, leading to preferable outcomes due to mutually opposite effects of these neurotransmitters on each other. The potential beneficial effects on dopamine synthesis and the survival of dopaminergic neurons could be mediated by DPP‐4 inhibition. These effective noncompetitive DPP‐4 inhibitors, with inhibitory potential better than reference diprotin A (relative inhibitory potency compared to diprotin A is 3.39 and 1.54 for compounds 7 and 5 , respectively), with the absence of cytotoxicity to SH‐SY5Y cells, are valuable candidates for further evaluation for the treatment of diabetes and associated disruption of neuronal homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsHumansAminesCell Line, TumorCell SurvivalDiabetes MellitusDose-Response Relationship, DrugHypoglycemic AgentsMolecular StructureStructure-Activity RelationshipOligopeptides

Stichwörter der Autor:innen

BenzimidazoleCytotoxicityDipeptidyl peptidase-4InhibitorsNoncompetitive DPP-4 inhibition

Substanzen

AminesBenzimidazolesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsDPP4 protein, humandiprotin AOligopeptides

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Medicine, University of Niš, Bulevar Dr Zorana Đinđića 81, 18000, Niš, Serbia.
  • Department of Chemistry, Faculty of Medicine, University of Niš, Bulevar Dr Zorana Đinđića 81, 18000, Niš, Serbia.
  • Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University, Düsseldorf, Universitätsstr, 1, 40225, Duesseldorf, Germany.
  • University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756, Sofia, Bulgaria.
  • Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev St., build. 9, 1113, Sofia, Bulgaria.

Förderung

  • Ministry of Science, Technological Development and Innovation
  • European Union - NextGenerationEU
  • National Recovery and Resilience Plan of the Republic of Bulgaria

Zitieren

APA

Tomović Pavlović, K., Ilić, B. S., Leitzbach, L., Anichina, K. K., Yancheva, D., Živković, A., Mavrova, A. T., Stark, H., & Šmelcerović, A. (2024). Bis(benzimidazol‐2‐yl)amine‐Based DPP‐4 Inhibitors Potentially Suitable for Combating Diabetes and Associated Nervous System Alterations. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202401227

Vancouver

Tomović Pavlović K, Ilić BS, Leitzbach L, Anichina KK, Yancheva D, Živković A, et al. Bis(benzimidazol‐2‐yl)amine‐Based DPP‐4 Inhibitors Potentially Suitable for Combating Diabetes and Associated Nervous System Alterations. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202401227

BibTeX
@article{TomoviPavlovi2024,
  author = {Tomović Pavlović, Katarina and Ilić, Budimir S and Leitzbach, Luisa and Anichina, Kameliya K and Yancheva, Denitsa and Živković, Aleksandra and Mavrova, Anelia Ts and Stark, Holger and Šmelcerović, Andrija},
  title = {Bis(benzimidazol‐2‐yl)amine‐Based DPP‐4 Inhibitors Potentially Suitable for Combating Diabetes and Associated Nervous System Alterations},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  doi = {10.1002/cbdv.202401227}
}
Kostenlos starten →